Chen Yiyang, Qin Xiaowen, Sun Li, Zhang Pu, Liu Zhenghong, Zheng Bin, Mou Yixuan, Li Haichang, Wang Heng, Zhang Dahong
The Second Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, China.
Department of Nutrition and Food Hygiene, The National Key Discipline,School of Public Health, Harbin Medical University, Harbin, China.
Biochem Genet. 2025 Jul 1. doi: 10.1007/s10528-025-11163-7.
Renal clear cell carcinoma is the most common histological form of renal cancer, but targeted therapy is still lacking. PSTPIP1 is associated with multiple immune-related pathways and is higher expressed in tumors. Thus, the correlation of PSTPIP1 and ccRCC (clear cell renal cell carcinoma) was studied to evaluate the therapeutic potential of PSTPIP1 as a target for tackling ccRCC. The expression of PSTPIP1 mRNA in clear cell renal cell carcinoma (ccRCC) was analyzed using the Oncomine, TCGA, UALCAN, GSCA, and GEPIA databases and analysis tools. Immunohistochemistry (IHC) was utilized to detect PSTPIP1 protein in clinical samples, and the chi-square test, univariate analysis and multivariate analysis were utilized to verify the relationship between PSTPIP1 and ccRCC. Co-expressed genes and enriched pathways were obtained from the TCGA and GSEA (Gene Set Enrichment Analysis) database and analysis tool. A protein-protein interaction network was constructed to support mechanism analysis. PSTPIP1 expression was significantly elevated in ccRCC tissues compared with normal renal tissues. PSTPIP1 expression levels showed significant correlations with tumor size, TNM stage, and PD-L1 status. Overexpression of PSTPIP1 was closely associated with patient survival, with high PSTPIP1 expression serving as a prognostic factor for reduced overall survival in ccRCC patients. Our findings indicate that high expression of PSTPIP1 is a predictor of poor prognosis in ccRCC patients, suggesting this protein may represent a potential therapeutic target for ccRCC treatment.
肾透明细胞癌是肾癌最常见的组织学类型，但仍缺乏靶向治疗。PSTPIP1与多种免疫相关途径有关，且在肿瘤中高表达。因此，研究了PSTPIP1与肾透明细胞癌（ccRCC）的相关性，以评估PSTPIP1作为治疗ccRCC靶点的治疗潜力。使用Oncomine、TCGA、UALCAN、GSCA和GEPIA数据库及分析工具分析肾透明细胞癌（ccRCC）中PSTPIP1 mRNA的表达。利用免疫组织化学（IHC）检测临床样本中的PSTPIP1蛋白，并采用卡方检验、单因素分析和多因素分析来验证PSTPIP1与ccRCC之间的关系。从TCGA和GSEA（基因集富集分析）数据库及分析工具中获得共表达基因和富集途径。构建蛋白质-蛋白质相互作用网络以支持机制分析。与正常肾组织相比，ccRCC组织中PSTPIP1表达显著升高。PSTPIP1表达水平与肿瘤大小、TNM分期和PD-L1状态显著相关。PSTPIP1的过表达与患者生存密切相关，PSTPIP1高表达是ccRCC患者总生存期降低的预后因素。我们的研究结果表明，PSTPIP1高表达是ccRCC患者预后不良的预测指标，提示该蛋白可能是ccRCC治疗的潜在靶点。
